Skip to main content
SpringerLink
Log in

Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Al-Shughai N, Al-Dawsari G, Gyger M et al (2007) Clinical significance of plasmacytosis in the day +14 bone marrow of patients with acute myeloid leukemia undergoing induction chemotherapy. J Clin Pathol 60:520–523

    Article  Google Scholar 

  2. Stein EM, DiNardo CD, Pollyea DA et al (2017) Enasidenib in IDH2 relapsed or refractory acute myeloid leukemia. Blood 130(6):722–731

    Article  CAS  Google Scholar 

  3. Kumar R, Srinivasan VK, Sharma P, Aggarwal R, Prakash G, Malhotra P, Varma N (2016) Synchronous plasma cell myeloma and acute myeloid leukemia in a therapy-naïve patient: a rare occurrence. Indian J Hematol Blood Transfus 32(Suppl 1):168–172

    Article  Google Scholar 

  4. Berthon C, Nudel M, Boyle EM et al (2020) Acute myeloid leukemia synchronous with multiple myeloma treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size. Leuk Res Rep 13:100202

    PubMed  PubMed Central  Google Scholar 

  5. Bergaggio E, Chiara R, Garaffo G et al (2019) IDH2 inhibition enhances proteasome inhibitor responsiveness in hematologic malignancies. Blood 133:156–167

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Atrium Health, Levine Cancer Institute, 100 Medical Park Drive, Concord, NC, 28025, USA

    Donald C. Moore

  2. NeoGenomics, Division of Hematopathology, 2110 Rutherford Rd, Carlsbad, CA, 92008, USA

    Viera Nelson

  3. Department of Hematology/Oncology, Atrium Health, Levine Cancer Institute, 1656 Riverchase Blvd, Rock Hill, SC, 29732, USA

    Alaa Muslimani

Authors
  1. Donald C. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Viera Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alaa Muslimani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donald C. Moore.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moore, D.C., Nelson, V. & Muslimani, A. Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma. Ann Hematol 100, 3053–3055 (2021). https://doi.org/10.1007/s00277-020-04285-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04285-y

Search

Navigation